Review of Coronavirus disease- 2019 (COVID-19) in Iraq

Huda Sahib Abdul Mohammed  Al-Rawazq

doi:10.30574/gscarr.2022.10.1.0307

Authors

Huda Sahib Abdul Mohammed Al-Rawazq Anatomy Department / biology, College of Medicine, Baghdad University, Baghdad, Iraq.

DOI:

https://doi.org/10.30574/gscarr.2022.10.1.0307

Keywords:

SARS-COV-2, Mutations, Pandemic, Coronavirus Disease -2019 (COVID-19), Iraq

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) or 2019 novel coronavirus (2019-nCoV) is quickly spreading to the rest of the world, from its origin in Wuhan, Hubei Province, China. And becoming a global pandemic that affects the world's most powerful countries. The goal of this review is to assist scientists, researchers, and others in responding to the current Coronavirus disease (covid-19) is a worldwide public health contingency state. This review discusses current evidence based on recently published studies which is related to the origin of the virus, epidemiology, transmission, diagnosis, treatment, and all studies in Iraq for the effect of covid-19 diseases, as well as provide a reference for future researchers. The findings of this review show significant differences across gender, age group, area of residence, environmental agents (temperature, humidity), and people with chronic diseases (hypertension, diabetes mellitus, heart disease, respiratory disorders, and immunocompromised disease). To control the pandemic, information about COVID-19 was disseminated to people, including wearing a face mask and using a social distancing strategy as an effective tool for controlling COVID-19. More education and progress are required to convince the public that the vaccine is both effective and safe.

Metrics

Metrics Loading ...

References

T Singhal. “A Review of Coronavirus Disease-2019 (COVID-19),” Indian J Pediatr. Apr 2020; 87(4): 281–286.

ZJ Cheng, J Shan. “Novel coronavirus: where we are and what we know,” Infection. Apr 2020; 48(2): 155–163.

JT Wu, K Leung, GM Leung. “Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study,” Lancet (London, England). Mar 2020; 395: 10225, 689.

D Gondauri, E Mikautadze, M Batiashvili. “Research on COVID-19 Virus Spreading Statistics based on the Examples of the Cases from Different Counties,” Electron J Gen Med. Mar 2020; 17(4).

C-C Lai, T- Shih, W-C Ko, H-J Tang, R Hsueh. “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges,” International Journal of Antimicrobial Agents. Mar 2020; 55(3): 105924.

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, “The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2,” Nat Microbiol. Apr 2020; 5(4): 536–544.

ASP, ADD, NG. “A Review on COVID-19 and Current Repurposing Treatment Strategy,” Indian Journal of Forensic Medicine & Toxicology. Aug 2021; 15(4): 4.

S Zhao, H Chen. “Modeling the epidemic dynamics and control of COVID-19 outbreak in China,” Quant Biol. Mar 2020; 8(1): 11–19.

Q Li et al., “Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia,” N Engl J Med. Mar 2020; 382(13): 1199–1207.

M Giovanetti, D Benvenuto, S Angeletti, M Ciccozzi. “The first two cases of 2019-nCoV in Italy: Where they come from?” Journal of Medical Virology. 2020; 92(5): 518–521.

D Paraskevis, EG. Kostaki, G Magiorkinis, G Panayiotakopoulos, G Sourvinos, S Tsiodras. “Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event,” Infect Genet Evol. Apr 2020; 79: 104212.

Y-R. Guo et al., “The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status,” Military Med Res. Dec 2020; 7(1): 11.

N Zhu et al., “A Novel Coronavirus from Patients with Pneumonia in China, 2019,” N Engl J Med. Feb 2020; 382(8): 727–733.

Y Yin, RG Wunderink. “MERS, SARS and other coronaviruses as causes of pneumonia,” Respirology. Feb 2018; 23(2): 130–137.

Zhou et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin,” Nature. Mar 2020; 579: 7798, 270–273.

W Guan et al., “Clinical Characteristics of Coronavirus Disease 2019 in China,” N Engl J Med. Apr 2020; 382(18): 1708–1720.

G Chowell et al., “Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study,” BMC Med. Dec 2015; 13(1): 210.

CK Kang et al., “Clinical and Epidemiologic Characteristics of Spreaders of Middle East Respiratory Syndrome Coronavirus during the 2015 Outbreak in Korea,” J Korean Med Sci. May 2017; 32(5): 744–749.

Z Khan, K Muhammad, A Ahmed, H Rahman. “Coronavirus outbreaks: prevention and management recommendations,” Drugs Ther Perspect. May 2020; 36(5): 215–217.

S Wang et al., “Experience of Clinical Management for Pregnant Women and Newborns with Novel Coronavirus Pneumonia in Tongji Hospital, China,” CURR MED SCI. Apr 2020; 40(2): 285–289.

LE Gralinski, VD Menachery. “Return of the Coronavirus: 2019-nCoV,” Viruses. Jan 2020; 12(2): E135.

S Adhikari et al., “Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review,” Infectious Diseases of Poverty. Mar 2020; 9(1): 29.

AA Mohammed, MN. Mustafa, SA Abdulsattar, AS Al-zaidi4. “COVID 19: Evaluate of Liver and Renal Function Tests in Iraqi Patients,” Medico Legal Update. Jan 2021; 21(1).

A Assiri et al., “Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study,” Lancet Infect Dis. Se 2013; 13(9): 752–761.

H Wang et al., “Factors associated with clinical outcome in 25 patients with avian influenza A (H7N9) infection in Guangzhou, China,” BMC Infectious Diseases. Oct 2016; 16(1): 534.

JF-W Chan et al., “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,” The Lancet. Feb 2020; 395: 10223, 514–523.

W Wang et al., “Detection of SARS-CoV-2 in Different Types of Clinical Specimens,” JAMA. May 2020; 323(18): 1843–1844.

Q-H Nie, X-D. Luo, W-L Hui. “Advances in clinical diagnosis and treatment of severe acute respiratory syndrome,” World J Gastroenterol. Jun 2003; 9(6): 1139–1143.

M Aljofan, A Gaipov. “Chloroquine and COVID-19: A Light at the End of the Tunnel, or is it Another Train?” Electron J Gen Med. Mar 2020; 17(4).

RK Zeldin, RA Petruschke. “Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients,” Journal of Antimicrobial Chemotherapy. Jan 2004; 53(1): 4–9.

CM Chu. “Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings,” Thorax. Mar 2004; 59(3): 252–256.

E De Clercq. “New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections,” Chemistry – An Asian Journal. 2019; 14(22): 3962–3968.

E Tchesnokov, JY Feng, D Porter, M Götte “Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir,” Viruses. Apr 2019; 11(4): Art. 4.

A Sebba. “Tocilizumab: The first interleukin-6-receptor inhibitor,” American Journal of Health-System Pharmacy. Aug 2008; 65(15): 1413–1418.

RN Maini et al., “Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate,” Arthritis & Rheumatism. 2006; 54(9): 2817–2829.

“Knowledge, Attitude, and Practice Regarding Coronavirus Disease-19: Population-Based Study in Iraq | Open Access Macedonian Journal of Medical Sciences,” Oct 2020.

H Dawood, A Hwayyiz, I Ibrahim, I Abdul Rahman. “The clinical features of COVID - 19 in a group of Iraqi patients: A record review,” JFacMedBagdad. May 2021; 63(1): 8–12.

“The frequency of persistent symptoms after acute COVID-19 among Iraqi patients Amen SO, Rasool BQ, Yousif SH, Shakir SS, Shekho BS - Med J Babylon.” https://www.medjbabylon.org/article.asp?issn=1812-156X;year=2021;volume=18;issue=3;spage=235;epage=240;aulast=Amen;type=0 (accessed Dec. 04, 2021).

Z Abbas, F Manhal. “Comorbidities and risk factors for COVID-19 in a group of Iraqi patients confirmed by real-time PCR test,” Journal Port Science Research. Apr 2021; 4(1): Art. 1.

AH Ad’hiah, RH Allami, RH Mohsin, MH Abdullah, AJR AL-Sa’ady, MY Alsudani. “Evaluating of the association between ABO blood groups and coronavirus disease 2019 (COVID-19) in Iraqi patients,” Egyptian Journal of Medical Human Genetics. Se 2020; 21(1): 50.

College of Health Sciences, Hawler Medical University , Erbil ,Iraq, R. Hwaiz, K. Ali, and N. Al-Tawil, “Effect of Lockdown,Temperature,and Humidity on the Pattern of COVID-19 in Erbil Province,Kurdistan Region, Iraq,” DJM. Jun 2021; 20(2): 56–67.

RM Al-Mosawi, “Survey on Cases of Coronavirus Disease (COVID-19) in Iraq during Months of Year 2020,” 2020; 2(2): 9.

M. Alkotaji and M. Khalaf, “Pulmonary surfactant in COVID-19; A role in etiology and treatment,” IJP. Dec 2020; 17(1): 115–134.

HA Hashim et al., “Controlled Randomized Clinical Trial on Using Ivermectin with Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq,” IRAQI JOURNAL OF MEDICAL SCIENCES. 2021; 19(1): 107–115.

MA Ahmed, ZNA Jalelli, MA Alani, FI Mostafa, AA Al-Hamdani. “Two-intervention social distancing strategy to control COVID-19 in Mosul city; A Comparative study,” 2020; 20(7).

IA Mohammed, AH Ali, JN Al shenaty, “Clinical course and disease outcomes in hospitalized patients with 2019 novel corona virus disease at Ibn- Al Khateeb Hospital in Baghdad, Iraq,” JFacMedBagdad. Jun 2020; 62(3).

O Habib, A AlKanan, ِa Abed, N Mohammed “Epidemiological Features of COVID-19 Epidemic in Basrah-Southern Iraq-First Report,” MJBU. Jun 2020; 38(1): 7–18.

OS Habib, HA Jassim, WJ Alshihaby, MA Mohammed. “The Dynamics of COVID-19 Epidemic in Basrah-Second Report,” The Medical Journal of Basrah University. 23 Nov 2021; 38(1).

A-RA Kadhim, DA Abdulwahid, A Aymen, E Abbas, A Laith. “Assessment of COVID-19 Related Misinformation among the Community in Basrah, Iraq,” Iraqi National journal of Medicine. 28 Mar 2021; 2(3).

BAA Hijaj, AK Al-Rubaye, ZT Al-Hashim, MA Mohammed, OS Habib. “A Study on 696 COVID-19 Cases in Basrah-Southern Iraq: Severity and Outcome Indicators,” Iraqi National journal of Medicine. 28 Mar 2021; 2(3).

MS Hussein, SALA Meani, MM Ahmed. “Prevalence of COVID-19 Pandemic in Province Of Anbar, Iraq,” NVEO - NATURAL VOLATILES & ESSENTIAL OILS Journal | NVEO. Nov 2021; 5292–5302.

Raghad G. Ali Al-Suhail and Layla Fouad Ali, “Statistical Analysis of COVID-19 Pandemic across the Provinces of Iraq,” eijs. Mar 2021; 811–824.

H. F. Ghazi et al., “ACCEPTANCE OF COVID-19 VACCINE AMONG GENERAL POPULATION IN IRAQ,” Iraqi National journal of Medicine. 28 Mar 2021; 3(1).